WEIHAI SHIDAI MARINE BIOTECHNOLOGY CO., LTD.

shidaimarine.com

As Asia's most professional manufacturer of liquid seaweed fertilizer, SHIDAI MARINE has been - engaged in an agriculture research program for 6 years - focused on kelp business and industry for more than 20 years - equipped with professional enzymolysis equipment over 300 sets - cultivating on a Laminaria Japonica farming base covering 1,000 hectares With all these experience, technology and resources, SHIDAI MARINE thus developed a process to extract essential nutrients from fresh kelp cells, while ultimately preserving their bioactivity beneficial to plant growth and development. And LJ KELP is therefore created accordingly. Numerous research programs have proved that LJ KELP plays a positive and effective role, especially in promoting root growth, flowering and fruits initiation and stress resistance.

Related News

IMMUNOSCAPE INTENSELY ENGAGED IN IMMUNOLOGY BREAKTHROUGHS FOR COVID-19 RAISED $11M IN A GLOBAL EQUITY FINANCING

ImmunoScape | August 13, 2020

news image

ImmunoScape (www.ImmunoScape.com), a biotech firm enabling unprecedented insights into the human immune system, today announced that it has raised USD $11 million (SGD $14.8 million) in a global equity financing round. US-based venture firm Anzu Partners led the round, joined by University of Tokyo Edge Capital (UTEC) in Japan, and NPR Holdings in Indonesia.ImmunoScape's immune profiling platform, which provides deep insights into the T-cells of the human immune system, is already inte...

Read More

BIOTECH STOCKS SURGE AS PEOPLE ARE HUNGRY FOR GOOD NEWS ON THE CORONAVIRUS

cnbc | April 17, 2020

news image

Biotech stocks surged Friday after new details on a closely watched clinical trial lifted hopes that scientists may be close to a treatment for the coronavirus, which continues to maintain its foothold across the globe after emerging a little over three months ago.The IBB, an ETF that tracks biotech’s biggest players, was up more than 2% Friday after health-care publication STAT News revealed early impressions from one of Gilead Sciences’ clinical trials for antiviral drug remdesivir...

Read More

CELL AND GENE THERAPY

EXACT SCIENCES ACQUIRES PREVENTIONGENETICS TO ACCELERATE AVAILABILITY OF HEREDITARY CANCER TESTING FOR MORE PATIENTS

Exact Sciences Corporation | January 10, 2022

news image

Exact Sciences Corp. announced it has acquired PreventionGenetics, a genetic testing laboratory, to complement its advanced cancer diagnostics portfolio and support its entrance into hereditary cancer testing (HCT). PreventionGenetics provides the clinical lab, expertise, and foundational technology necessary to accelerate the availability of HCT and help more patients know their germline risk of cancer and other diseases. "PreventionGenetics is a natura...

Read More

CELL AND GENE THERAPY

AKTIS ONCOLOGY ANNOUNCES ACTINIUM-225 SUPPLY AGREEMENTS WITH LEADING ISOTOPE PRODUCERS

Aktis Oncology | August 24, 2022

news image

Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced agreements with three leading medical radioisotope manufacturers NorthStar Medical Radioisotopes LLC, Niowave, Inc, and TerraPower LLC, for preclinical, clinical, and commercial supply of Actinium-225. "Given the breadth and depth of our emerging pipeline, securing robust isotope s...

Read More
news image

IMMUNOSCAPE INTENSELY ENGAGED IN IMMUNOLOGY BREAKTHROUGHS FOR COVID-19 RAISED $11M IN A GLOBAL EQUITY FINANCING

ImmunoScape | August 13, 2020

ImmunoScape (www.ImmunoScape.com), a biotech firm enabling unprecedented insights into the human immune system, today announced that it has raised USD $11 million (SGD $14.8 million) in a global equity financing round. US-based venture firm Anzu Partners led the round, joined by University of Tokyo Edge Capital (UTEC) in Japan, and NPR Holdings in Indonesia.ImmunoScape's immune profiling platform, which provides deep insights into the T-cells of the human immune system, is already inte...

Read More
news image

BIOTECH STOCKS SURGE AS PEOPLE ARE HUNGRY FOR GOOD NEWS ON THE CORONAVIRUS

cnbc | April 17, 2020

Biotech stocks surged Friday after new details on a closely watched clinical trial lifted hopes that scientists may be close to a treatment for the coronavirus, which continues to maintain its foothold across the globe after emerging a little over three months ago.The IBB, an ETF that tracks biotech’s biggest players, was up more than 2% Friday after health-care publication STAT News revealed early impressions from one of Gilead Sciences’ clinical trials for antiviral drug remdesivir...

Read More
news image

CELL AND GENE THERAPY

EXACT SCIENCES ACQUIRES PREVENTIONGENETICS TO ACCELERATE AVAILABILITY OF HEREDITARY CANCER TESTING FOR MORE PATIENTS

Exact Sciences Corporation | January 10, 2022

Exact Sciences Corp. announced it has acquired PreventionGenetics, a genetic testing laboratory, to complement its advanced cancer diagnostics portfolio and support its entrance into hereditary cancer testing (HCT). PreventionGenetics provides the clinical lab, expertise, and foundational technology necessary to accelerate the availability of HCT and help more patients know their germline risk of cancer and other diseases. "PreventionGenetics is a natura...

Read More
news image

CELL AND GENE THERAPY

AKTIS ONCOLOGY ANNOUNCES ACTINIUM-225 SUPPLY AGREEMENTS WITH LEADING ISOTOPE PRODUCERS

Aktis Oncology | August 24, 2022

Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced agreements with three leading medical radioisotope manufacturers NorthStar Medical Radioisotopes LLC, Niowave, Inc, and TerraPower LLC, for preclinical, clinical, and commercial supply of Actinium-225. "Given the breadth and depth of our emerging pipeline, securing robust isotope s...

Read More